Jointown Pharmaceutical Group maintained a moderate ROCE of ...
Jointown Pharmaceutical Group maintained a moderate ROCE of 12% but didn't provide high returns to shareholders over five years. Its high liabilities to total assets ratio points to a significant dependency on short-term creditors.
Returns At Jointown Pharmaceutical Group (SHSE:600998) Appear To Be Weighed Down
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment